MARKET

IOVA

IOVA

Iovance
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.22
-0.95
-3.15%
Pre Market: 28.80 -0.42 -1.44% 07:00 05/06 EDT
OPEN
30.38
PREV CLOSE
30.17
HIGH
31.47
LOW
28.89
VOLUME
325
TURNOVER
--
52 WEEK HIGH
54.21
52 WEEK LOW
24.67
MARKET CAP
4.45B
P/E (TTM)
-15.2386
1D
5D
1M
3M
1Y
5Y
Iovance Biotherapeutics Q1 Earnings Preview
Iovance Biotherapeutics (NASDAQ:IOVA) is scheduled to announce Q1 earnings results on Thursday, May 6th, after market close.The consensus EPS Estimate is -$0.49 (+10.9% Y/Y)Over the last 1 year, IOVA has
Seekingalpha · 14h ago
Notable earnings after Thursday's close
[[ACMR]], [[AGO]], [[AIG]], [[AL]], [[ALTR]], [[AMBC]], [[AMC]], [[AMH]], [[AMN]], [[ANGI]], [[APPN]], [[AQN]], [[AVLR]], [[AXNX]], [[AXON]], [[BCC]], [[BECN]], [[BILL]], [[BL]], [[BYND]], [[CABO]], [[CARG]], [[CDK]], [[CERT]], [[CGNX]], [[CHUY]], [[CLI]],...
Seekingalpha · 14h ago
Iovance Biotherapeutics to Present at Upcoming Conferences
SAN CARLOS, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that senior leadership plans to present at the follo...
GlobeNewswire · 1d ago
--Truist Securities Starts Iovance Biotherapeutics at Buy With $50 Price Target
MT Newswires · 3d ago
Week Ahead In Biotech (May 2-8): ChemoCentryx Adcom, Ophthalmology Conference Presentations, Earnings Deluge
Biopharma stocks experienced volatility in the week ended April 30, as stocks reacted to earnings, data readouts and a handful of FDA decisions.
Benzinga · 4d ago
Iovance Biotherapeutics to Present Clinical Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting
Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study Initial Data for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor Naïve Advanced Melanoma Cohort 1A in IOV-COM-202 Clinical Study SAN CARLOS, Calif., April 28, 2021...
GlobeNewswire · 04/28 15:50
Iovance Biotherapeutics To Present Clinical Data For Lifileucel In Advanced Melanoma At ASCO 2021 Annual Meeting
Iovance Biotherapeutics to Present Clinical Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting Updated Lifileucel Data from Cohort 2 in C-144-01 Clinical Study   Initial Data for Lifileucel in
Benzinga · 04/28 14:52
Iovance Biotherapeutics to Host First Quarter Financial Results Conference Call and Webcast on Thursday, May 6, 2021
SAN CARLOS, Calif., April 27, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report its first quarter financial results on Thursday, May 6...
GlobeNewswire · 04/27 21:01
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IOVA. Analyze the recent business situations of Iovance through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 14 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IOVA stock price target is 55.31 with a high estimate of 97.00 and a low estimate of 35.00.
EPS
Institutional Holdings
Institutions: 377
Institutional Holdings: 164.39M
% Owned: 108.04%
Shares Outstanding: 152.16M
TypeInstitutionsShares
Increased
83
20.14M
New
57
3.54M
Decreased
95
11.15M
Sold Out
38
3.56M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.92%
Pharmaceuticals & Medical Research
+0.20%
Key Executives
Chairman/Director
Iain Dukes
President/Chief Executive Officer/Director
Maria Fardis
Chief Financial Officer
Bellemin Shall
Chief Financial Officer/Chief Accounting Officer
Jean-marc Bellemin
Chief Operating Officer
Igor Bilinsky
Vice President - Finance
Michael Swartzburg
General Counsel/Secretary
Frederick Vogt
Other
Friedrich Graf Finckenstein
Director
Athena Countouriotis
Independent Director
Ryan Maynard
Independent Director
Merrill McPeak
Independent Director
Wayne Rothbaum
Independent Director
Michael Weiser
No Data
About IOVA
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient’s own immune system to eradicate cancer cells. The Company has developed a shorter manufacturing process for Tumor infiltrating lymphocyte (TIL) therapy known as Generation 2 (Gen 2), which yields a cryopreserved TIL product. Its lead product candidates include lifileucel for metastatic melanoma and LN-145 for metastatic cervical cancer. In addition to metastatic melanoma and metastatic cervical cancer, it is investigating TIL therapy and peripheral blood lymphocyte therapy for the treatment of squamous cell carcinoma of the head and neck, non-small cell lung cancer and chronic lymphocytic leukemia.

Webull offers kinds of Iovance Biotherapeutics Inc stock information, including NASDAQ:IOVA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IOVA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IOVA stock methods without spending real money on the virtual paper trading platform.